Welcome to our dedicated page for LifeStance Health Group news (Ticker: LFST), a resource for investors and traders seeking the latest updates and insights on LifeStance Health Group stock.
LifeStance Health Group reports developments as a Nasdaq-listed provider of virtual and in-person outpatient mental healthcare. The company serves children, adolescents and adults through psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy.
Recurring news themes include quarterly operating results, visit volumes, clinician productivity, center-level margin trends, cash flow, debt and capital allocation. Company updates also cover secondary common stock offerings by selling stockholders, share repurchase activity, investor conference presentations, executive and board changes, and corporate-status announcements tied to its outpatient mental health services business.
LifeStance Health Group (NASDAQ: LFST) will be added to the S&P SmallCap 600 prior to trading on May 1, 2026. Golden Entertainment (NASDAQ: GDEN) will be deleted from the index on the same date, following a pending acquisition by VICI Properties and Blake Sartini.
The table of changes lists LFST as an addition to the Health Care sector and GDEN as a deletion from Consumer Discretionary.
LifeStance Health Group (NASDAQ: LFST) will release its first quarter 2026 earnings before the market opens on Thursday, May 7, 2026, and host a live conference call at 8:30 a.m. ET.
Investors can join by dialing 1-800-715-9871 (U.S.) or 1-646-307-1963 (international) with conference ID 8795477, or listen via the company's Investor Relations Events and Presentations webcast. Related materials and a replay will be posted on the Investor Relations website.
LifeStance (NASDAQ:LFST) published clinical outcomes from an analysis of nearly 180,000 patients who began care between Sept 2024 and Dec 2025. The results show 79% of patients had clinically significant anxiety improvement and 73% had clinically significant depression improvement.
Assessments used the GAD-7 and PHQ-9, findings were consistent across all 33 states served, and LifeStance attributes results to its measurement-informed care model combining therapy, medication management, in-person and telehealth options.
LifeStance Health Group (Nasdaq: LFST) announced on February 25, 2026 that certain selling stockholders intend to offer 25,000,000 shares of common stock under an existing shelf registration. The company will not sell shares and will not receive proceeds.
LifeStance authorized a concurrent repurchase of 7,000,000 shares from the underwriter, subject to the offering’s completion and customary conditions; J.P. Morgan is the underwriter. The shelf registration became effective on May 21, 2024. The repurchase price will match the offering price and the underwriter will not receive fees on repurchased shares.
LifeStance (Nasdaq: LFST) reported Q4 2025 revenue of $382.2M (up 17%) and full-year revenue of $1,424.3M (up 14%). FY Adjusted EBITDA was $157.7M and net income was $9.7M. The company generated $146.2M cash from operations and ended Q4 with $248.6M cash and $265.9M net long-term debt. The Board approved a $100M share repurchase program and provided 2026 guidance calling for $1.615B–$1.655B revenue and $185M–$205M Adjusted EBITDA.
LifeStance Health (NASDAQ: LFST) will release fourth quarter and full year 2025 results before the market opens on Wednesday, February 25, 2026, and will host a live earnings conference call the same day at 8:30 a.m. ET.
Investors may join by phone using conference ID 3993891 or listen via the LifeStance Investor Relations webcast; replay and related materials will be posted on the IR website.
LifeStance Health Group (Nasdaq: LFST) reported third-quarter 2025 results for the period ended September 30, 2025. Revenue rose 16% year-over-year to $363.8M driven by a 17% increase in visit volumes and an 11% increase in clinicians to 7,996. Adjusted EBITDA increased 31% to $40.2M (11.1% margin) and the company posted net income of $1.1M versus a prior-year loss. Center Margin grew 16% to $116.6M (32.0% of revenue). Cash from operations was $27.3M in Q3 with ending cash of $203.9M and net long-term debt of $269.4M. Full-year 2025 guidance reiterated for revenue $1.41B–$1.43B and raised Adjusted EBITDA to $146M–$152M.
LifeStance Health (NYSE:LFST) released a national survey on Nov. 5, 2025, measuring how the holiday season affects mental health. Key findings: 57% find the holidays stressful, 69% feel pressure to appear happier, and 51% report loneliness even when with loved ones. Younger adults are hardest hit: Millennials and Gen Z report the highest desire to skip events and the greatest pressure to perform emotionally.
The survey sampled 1,023 U.S. adults from Oct. 16–21, 2025, with a ±4 point credibility interval. LifeStance highlights access to flexible and remote outpatient care.
LifeStance Health (NASDAQ: LFST) will present at the UBS Global Healthcare Conference in Palm Beach Gardens, FL on Monday, November 10, 2025 at 4:15 p.m. ET. CEO Dave Bourdon will present and the session will be moderated by Kevin Caliendo.
The presentation will be webcast live and a replay will be available in the Events and Presentations section of the LifeStance Health Investor Relations website.
Calm Health (LFST) announced a partnership with LifeStance Health on October 28, 2025 to streamline access to licensed mental health care. Calm Health users complete a screening and receive a personalized plan that can now refer higher‑acuity cases directly to LifeStance.
Key points: Calm Health is available to more than 26 million people; LifeStance operates across 550+ centers, offers virtual and in‑person therapy, accepts most insurance plans, and patients can typically schedule first appointments within one week or less.